EXPERT, EXPosurE Registry RiociguaT in Patients With Pulmonary Hypertension
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 13 Sep 2017
At a glance
- Drugs Riociguat (Primary)
- Indications Pulmonary hypertension
- Focus Adverse reactions
- Acronyms EXPERT
- Sponsors Bayer
- 12 Jul 2017 Planned End Date changed from 1 Aug 2018 to 1 Jul 2018.
- 19 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 24 May 2017 Interim results (n=713; As of July 10, 2016) presented at the 113th International Conference of the American Thoracic Society